W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Resampling phase III data to assess phase II trial designs and endpoints
Manish R. Sharma,Theodore Karrison,Yuyan Jin,Robert R. Bies,Michael L. Maitland,Walter M. Stadler,Mark J. Ratain +6 more
TL;DR: Compared with the single-arm design and the randomized design comparing PFS, the randomized phase II design with the log ratio endpoint has greater power to predict the positive phase III result of sorafenib in renal cancer, but a higher false positive rate for the negative phase III Results.
Journal ArticleDOI
The Role of Chemotherapy in Upper Tract Urothelial Carcinoma
TL;DR: It is argued that cisplatin-based neoadjuvant chemotherapy should be the standard of care for patients with locally advanced upper tract urothelial cancer.
Journal ArticleDOI
Saracatinib as a metastasis inhibitor in metastatic castration‐resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study
Edwin M. Posadas,Rafi S. Ahmed,Theodore Karrison,Russell Z. Szmulewitz,Peter H. O'Donnell,James L. Wade,James Shen,Murali Gururajan,Margarit Sievert,Walter M. Stadler +9 more
TL;DR: Treatment with saracatinib would increase the time required to develop new metastatic lesions due to a relationship between Fyn expression and directional motility, a cellular process related to metastasis.
Journal ArticleDOI
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures.
TL;DR: Several advances have recently demonstrated the robust detection of microRNAs from various biofluids, thus providing an additional opportunity for obtaining bioinformatically derived biomarkers to accelerate the identification of individual patients for personalized therapy.
Journal ArticleDOI
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Maria I. Carlo,Veda N. Giri,Channing J. Paller,Wassim Abida,Joshi J. Alumkal,Tomasz M. Beer,Himisha Beltran,Daniel J. George,Elisabeth I. Heath,Celestia S. Higano,Rana R. McKay,Alicia K. Morgans,Alicia K. Morgans,Akash Patnaik,Charles J. Ryan,Charles J. Ryan,Edward M. Schaeffer,Edward M. Schaeffer,Walter M. Stadler,Mary-Ellen Taplin,Noah D. Kauff,Jacob Vinson,Emmanuel S. Antonarakis,Heather H. Cheng,Heather H. Cheng +24 more
TL;DR: Assessment of current institutional practices, a framework to address unique challenges in this population, and identified areas of future research are developed.